CDEK
← All organizations

Progenics

For profitContributed to NME

Also known as: Progenics Pharmaceuticals, Inc. | PROGENICS PHARMS INC | Vice President, Clinical Research, Progenics Pharmaceuticals, Inc.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Apr 1, 2002

First marketed drug

Apr 24, 2008

First NDA

Apr 24, 2008

Last known activity

Dec 31, 2024

Acquired by Lantheus Medical Imaging on Oct 2, 2019

Timeline

1980s

  1. Jan 1, 1986

    Progenics— Founded

2000s

  1. Apr 24, 2008

    methylnaltrexone— NDA Organization

2010s

  1. Jan 1, 2013

    Molecular Insight Pharmaceuticals— Acquired

  2. Jul 30, 2018

    iobenguane sulfate i-131— NDA Secondary Org

  3. Oct 2, 2019

    Lantheus Medical Imaging— Acquired By

2020s

  1. May 26, 2021

    piflufolastat— Marketing Organization

Drugs by trial phase (25 distinct, 73 trials)

Phase 4 (2 own, 0 via acquisition)

Phase 3 (0 own, 1 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (3)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Tarrytown, NY, US Jan 1, 1986
First NDA
Apr 24, 2008
Last known activity
Dec 31, 2024